{"nctId":"NCT03954626","briefTitle":"Study to Collect Safety and ECG Data on Brolucizumab 6 mg Intravitreal Treatment in Patients With Wet AMD","startDateStruct":{"date":"2019-06-07","type":"ACTUAL"},"conditions":["Age-Related Macular Degeneration","Macular Degeneration","Wet Macular Degeneration","Retinal Degeneration","Retinal Diseases","Eye Diseases"],"count":14,"armGroups":[{"label":"RTH258","type":"EXPERIMENTAL","interventionNames":["Biological: brolucuzumab 6 mg IVT"]}],"interventions":[{"name":"brolucuzumab 6 mg IVT","otherNames":["RTH258"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Signed informed consent MUST be obtained prior to participation in the study\n* Study eye is diagnosed with nAMD and deemed to be eligible for intravitreal injection at the discretion of the Investigator\n\nExclusion Criteria:\n\n* Concomitant conditions or ocular disorders in the study eye at screening which may cause safety concerns on the judgement of the investigator\n* Any active intraocular or periocular or systemic infection or active intraocular inflammation at Baseline\n* Treatment with any ocular intravitreal injection in the study eye within the past 7 half lives prior to Baseline\n* Intraocular surgery, prior long-acting therapeutic agent, or ocular drug release device implantation (approved or investigational) in the study eye any time during the past 3 months prior to Baseline\n* Diagnosis of ECG abnormalities including:\n* Clinically significant cardiac arrhythmias, e.g., atrial fibrillation, sustained ventricular tachycardia, and clinically significant second or third degree AV block without a pacemaker\n* Familial long QT syndrome or known family history of Torsades de Pointes\n* Resting heart rate \\< 50 or \\> 90 bpm at screening\n* Resting QTcF ≥ 450 ms (male) or ≥ 460 ms (female) at screening\n* Use of concomitant medications that are classified as known risk, conditional risk or possible risk to prolong QT/QTc interval within 7 half-lives prior to Baseline\n* History of stroke (including transient ischemic attack, reversible ischemic neurological deficit, prolonged reversible ischemic neurological deficit) or myocardial infarction (ST or non-ST elevation myocardial infarction) at any time prior to baseline\n* Chronic kidney disease as determined as a CrCL at screening of \\< 60 ml/min/1.73 m2 as determined by the MDRD formula\n* Uncontrolled high blood pressure defined as a systolic value ≥ 140 mmHg or diastolic value ≥ 90 mmHg at screening or baseline\n* Systemic anti-VEGF therapy during the 6-month period prior to baseline\n* Electrolyte disturbances determined as out of normal range sodium, potassium or calcium serum concentrations at screening\n* Concomitant intake of long-acting muscarinic antagonist (LAMA)/ long-acting beta adrenergic (LABA) combination therapy\n* History of hypersensitivity to any of the study drugs or its excipients or to drugs of similar classes as assessed by the investigator\n* Use of systemic or ocular (including intravitreal) investigational drugs within 7 half-lives of baseline, (or within 30 days/until the expected pharmacodynamic effect has returned to baseline), whichever is longer or longer if required by local regulations (observational clinical studies solely involving over-the-counter vitamins, supplements, or diets are not exclusionary)\n* Pregnant or nursing (lactating) women","healthyVolunteers":false,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Frequency of Clinically Relevant Treatment Emergent ECG Changes After Intravitreal Injection of Brolucizumab 6 mg in Patients With nAMD","description":"Incidence between 20 and 24 h post-injection of clinically relevant treatment emergent changes in heart rate (HR), pulse rate (PR), QRS, and QTc (heart rate corrected QT using Fridericia's formula, QTcF) interval (ms). This is a composite endpoint capturing all 4 parameters and 3 time-points in one Outcome Measure.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":14},"commonTop":["Intraocular pressure increased"]}}}